Martin MIBS - Eli Lilly VP Projects

All Insiders . Mexico . 
Stock . Eli Lilly and . Stakeholders . Insider . Martin MIBS
LLY Stock  MXN 15,847  249.27  1.55%   

Insider

Martin MIBS is VP Projects of Eli Lilly and
Age 60
Phone317 276 2000
Webhttps://www.lilly.com

Eli Lilly Management Efficiency

The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.
Eli Lilly and has accumulated 15.35 B in total debt with debt to equity ratio (D/E) of 648.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Eli Lilly has a current ratio of 1.1, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Eli Lilly until it has trouble settling it off, either with new capital or with free cash flow. So, Eli Lilly's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eli Lilly sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eli to invest in growth at high rates of return. When we think about Eli Lilly's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nicole MurphyBiogen Inc
N/A
Michael CPABiogen Inc
59
Claudia BockstiegelRoche Holding AG
59
Michael HenckeBiogen Inc
N/A
Pascale SchmidtRoche Holding AG
50
Michael QuigleyGilead Sciences
N/A
Susan EsqBiogen Inc
66
Deborah TelmanGilead Sciences
58
Linda HigginsGilead Sciences
61
Barbara SchadlerRoche Holding AG
61
Jyoti MehraGilead Sciences
47
Diane WilfongGilead Sciences
61
Johannes MDRoche Holding AG
66
Thomas SchineckerRoche Holding AG
48
Natacha GassenbachBiogen Inc
N/A
Bruno EschliRoche Holding AG
N/A
Christopher ViehbacherBiogen Inc
63
Jacquie CFAGilead Sciences
N/A
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people. Eli Lilly and (LLY) is traded on Mexican Exchange in Mexico and employs 47 people.

Management Performance

Return On Equity0.65
Return On Asset0.11

Eli Lilly Leadership Team

Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines
Alonzo Weems, VP Officer
Jacob Naarden, CEO VP
Diogo Rau, VP Officer
Donald Zakrowski, Chief Fin
Anat Ashkenazi, VP CFO
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications
Martin MIBS, VP Projects
Anat JD, Gen VP

Eli Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.65
Return On Asset0.11
Profit Margin0.22 %
Operating Margin0.29 %
Current Valuation6.99 T
Shares Outstanding950.18 M
Shares Owned By Insiders0.15 %
Shares Owned By Institutions85.00 %
Price To Earning333.06 X
Price To Book34.76 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY